On Tuesday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: BioLineRx, Ltd. (NASDAQ:BLRX), FMSA Holdings Inc. (NYSE:FMSA), Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), Coronado Biosciences, Inc. (NASDAQ:CNDO)
BioLineRx, Ltd. (NASDAQ:BLRX), with shares gained 9.09%, closed at $2.28.
FMSA Holdings Inc. (NYSE:FMSA), with shares jumped 8.93%, settled at $6.22.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), with shares climbed 8.88%, and closed at $4.78.
Coronado Biosciences, Inc. (NASDAQ:CNDO), surged 8.63%, and closed at $4.28.
Latest NEWS regarding these Stocks are depicted underneath:
BioLineRx, Ltd. (NASDAQ:BLRX)
BioLineRx, Ltd. (BLRX), stated its financial results for the year ended December 31, 2014.
Kinneret Savitsky, Ph.D., CEO of BioLineRx, remarked, “2014 marks a year of noteworthy progress for BioLineRx on multiple fronts, both from a product development perspective, in addition to from a business perspective. We have continued our focus on the therapeutic areas of oncology and immunology, while increasing the emphasis on our clinical-stage programs.”
Financial Results for Year Ended December 31, 2014:
- Research and development expenses for the year ended December 31, 2014 were NIS 42.5 million ($10.9 million), a decrease of NIS 1.6 million ($0.4 million), or 3.7%, contrast to NIS 44.1 million ($11.3 million) for the year ended December 31, 2013. The decrease resulted primarily from termination of the BL-1020 CLARITY clinical trial in March 2013 and certain one-time costs associated with several clinical-stage projects in 2013, partially offset by raised spending on BL-8040, BL-7010 and BL-5010 in 2014.
- Sales and marketing expenses for the year ended December 31, 2014 were NIS 5.7 million ($1.5 million), an raise of NIS 1.6 million ($0.4 million), or 38.6%, contrast to NIS 4.1 million ($1.1 million) for the year ended December 31, 2013. The raise resulted primarily from professional fees related to raised business development activities, counting professional services related to the partnership contract with Novartis and the out-licensing contract with Omega regarding BL-5010.
- General and administrative expenses for the year ended December 31, 2014 were NIS 13.6 million ($3.5 million), an raise of NIS 0.4 million ($0.1 million) or 2.8%, contrast to NIS 13.2 million ($3.4 million) for the year ended December 31, 2013. The small raise resulted primarily from an raise in salary-related payments.
- The Corporation’s operating loss for the year ended December 31, 2014 amounted to NIS 61.7 million ($15.9 million), contrast with an operating loss of NIS 61.4 million ($15.8 million) for the year ended December 31, 2013.
- The Corporation recognized net non-operating revenue of NIS 11.0 million ($2.8 million) for the year ended December 31, 2014, an raise of NIS 6.8 million ($1.7 million), contrast to net non-operating revenue of NIS 4.2 million ($1.1 million) for the year ended December 31, 2013. Non-operating revenue for both periods primarily relates to fair-value adjustments of liabilities on account of warrants issued in the private and direct placements conducted in February 2012 and 2013. These fair-value adjustments were highly influenced by the Corporation’s share price at each period end (revaluation date).
- Net financial revenue amounted to NIS 11.2 million ($2.9 million) for the year ended December 31, 2014, a change of NIS 15.5 million ($4.0 million), contrast to net financial expenses of NIS 4.3 million ($1.1 million) for the year ended December 31, 2013. Net financial revenue and expenses result primarily from changes in the average exchange rate of the dollar in relation to the NIS during the respective periods, which have a direct effect on the Corporation’s net assets denominated in dollars.
- The Corporation’s net loss for the year ended December 31, 2014 amounted to NIS 39.6 million ($10.2 million), contrast with a net loss of NIS 61.4 million ($15.8 million) for the year ended December 31, 2013.
- The Corporation held NIS 134.9 million ($34.7 million) in cash, cash equivalents and short-term bank deposits as of December 31, 2014. In March 2015, the Corporation accomplished an underwritten public offering of its American Depositary Shares for gross proceeds of $28.8 million.
- Net cash used in operating activities was NIS 56.4 million for the year ended December 31, 2014, contrast with NIS 70.5 million for the year ended December 31, 2013. The NIS 14.1 million decrease in net cash used in operating activities during 2014 resulted primarily from a large decrease in net trade payables and accruals during the 2013 period.
- Net cash used in investing activities for the year ended December 31, 2014 was NIS 70.7 million, contrast to net cash used for investing activities of NIS 19.8 million for the year ended December 31, 2013. The changes in cash flows from investing activities relate primarily to investments in, and maturities of, short-term bank deposits and other investments during the respective periods.
- Net cash offered by financing activities for the year ended December 31, 2014 was NIS 117.8 million, contrast to net cash offered by financing activities of NIS 55.2 million for the year ended December 31, 2013. The cash flows from financing activities in 2014 primarily reflect the underwritten public offering in March 2014 and the investment by Novartis in December 2014. The cash flows from financing activities in 2013 reflect the direct placement to OrbiMed accomplished in February 2013, in addition to funding under the previous share purchase contract with LPC.
BioLineRx Ltd., a clinical stage biopharmaceutical development corporation, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The corporation’s development pipeline comprises of clinical-stage therapeutic candidates, counting BL-1040, a novel polymer solution for use in the prevention of ventricular remodeling following an acute myocardial infarction; BL-8040, a novel peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a novel polymer for the treatment of celiac disease; BL-5010, a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally accessible treatment for the hepatitis C virus and other viral indications.
FMSA Holdings Inc. (NYSE:FMSA)
FMSA Holdings Inc. (FMSA), declared results for the fourth quarter and full year ended December 31, 2014.
Fourth-Quarter 2014 Results:
For the fourth quarter, net revenue was $37.9 million, or $0.23 per diluted share, contrast with net revenue of $10.7 million, or $0.06 per diluted share, for the same period a year ago. Adjusted earnings per diluted share were $0.24, an raise of 118% over adjusted earnings per diluted share of $0.11 for the fourth quarter of 2013. The rise in earnings was primarily due to a 14% raise in raw sand sales volumes and a 44% raise in value-added coated product sales volumes. The quarterly and full-year comparisons of net revenue and earnings per share were influenceed by a number of non-operating charges in both periods, which are offered in the accorporationing table. Adjusted EBITDA for the fourth quarter was $100.4 million, up 56% over fourth-quarter 2013 adjusted EBITDA of $64.1 million.
Fourth-quarter proceed totaled $353.8 million, up 29% from $274.5 million for the same period in 2013. The raise in quarterly proceed was primarily due to raised sales volumes and the influence of price raises taken during 2014 in the corporation’s Proppant Solutions segment. Overall sales volumes raised to 2.5 million tons for the quarter, a 15% raise contrast with 2.2 million tons in the fourth quarter of 2013. The volume growth was driven by continued proppant demand across all basins. Contrast with the preceding-year period, fourth-quarter volumes were favorably influenced by raised unit train shipments, faster throughput at the corporation’s in-basin terminals and improved rail service, all of which led to improved delivery efficiencies for customers.
Full-Year 2014 Results:
For full-year 2014, net revenue was $170.4 million, or $1.03 per diluted share, contrast with net revenue of $104.0 million, or $0.63 per diluted share, for the preceding year. Adjusted earnings per diluted share were $1.07, an raise of 43% over adjusted earnings per diluted share of $0.75 for 2013. The raise was driven by the rise in sales volumes for coated products and an raise in sales volumes and selling prices for raw sand, partially offset by higher SG&A costs, counting additional costs to support sales and marketing for the Proppant Solutions segment, IPO and public corporation-related costs, expenditures to enhance the corporation’s logistics capabilities, and costs to support the growth of the business. Adjusted EBITDA for 2014 was $397.3 million, up 36% over 2013 adjusted EBITDA of $292.6 million. Adjusted EBITDA for 2014 was negatively influenced by $3 million of bad debt and litigation reserves that were not anticipated when the corporation offered full-year adjusted EBITDA guidance of $390 million to $395 million.
Full-year proceed totaled $1.36 billion, up 37% from $988.4 million in 2013. Sales volumes totaled 9.6 million tons, a 27% raise contrast with 7.6 million tons in the preceding year.
FMSA Holdings Inc., together with its auxiliaries, primarily provides sand-based proppant solutions for oilfield service, and exploration and production companies to enhance the productivity of their oil and gas wells. It operates in two segments, Proppant Solutions and Industrial & Recreational Products.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)
Anthera Pharmaceuticals, Inc. (ANTH), declared that it has accomplished the formerly declared underwritten public offering of 5,555,556 shares of its ordinary stock, offered at a price of $4.50 per share. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 833,333 shares of ordinary stock to cover over-allotments, if any. The gross proceeds to the Corporation from the sale of shares in this offering, before deducting customary underwriting discounts and commissions, were about $25,000,000 million. Anthera intends to use the net proceeds from this offering for clinical research and development and general corporate purposes.
Piper Jaffray & Co. has acted as sole underwriter in the offering. The Trout Group, LLC has acted as advisor to the Corporation.
Anthera Pharmaceuticals, Inc., a biopharmaceutical corporation, focuses on developing and commercializing products to treat diseases associated with inflammation and autoimmune diseases. It is developing blisibimod, a Phase III product candidate that targets elevated levels of B-cell activating factor associated with various B-cell mediated autoimmune diseases, counting systemic lupus erythematosus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. The corporation was founded in 2004 and is headquartered in Hayward, California.
Coronado Biosciences, Inc. (NASDAQ:CNDO)
Formerly on March 19, Coronado Biosciences, Inc. (CNDO), declared the formation of a new corporation, Mustang Therapeutics, Inc. Mustang will initially focus on the preclinical and clinical development, in addition to commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology. This portfolio of CAR-T cells was developed by Dr. Stephen Forman, Director, T cell Therapeutics Research Laboratory and the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, and Dr. Christine Brown, Associate Director, T cell Therapeutics Research Laboratory and Associate Research Professor. The deal is valued in excess of $40 million for the development of these CAR-T cells via up-front and milestone payments to City of Hope. It is anticipated that the first two CAR-T cells from this partnership will start enrollment in human clinical trials at the City of Hope this year.
Dr. Lindsay Rosenwald, Coronado Biosciences’ Chairman and CEO, commented, “The development of Chimeric Antigen Receptor T-cells for serious, refractory cancers is a burgeoning field of oncology. The engineering of patients’ immune cells to treat cancers may have a dramatic effect in cancer therapy. We are excited to have formed this partnership with the City of Hope and the laboratory of Dr. Stephen Forman.”
Coronado Biosciences, Inc., a biopharmaceutical corporation, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. Its principal pharmaceutical product candidates in clinical development comprise Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis, or autism spectrum disorder; and CNDO-109, a biologic that activates the immune system’s natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
